Skip to main content
    G

    GT Biopharma Inc (GTBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.35 (-10.04%)

    Market Cap: $7.67M

    Last updated: Nov 17, 2026 at 4:42 PM ET

    GT Biopharma Inc (GTBP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    GT Biopharma (GTBP) has a market cap of $7.67M. Its share count is up 28666.26% from a year earlier. It holds $9.92M more cash than debt, 129.42% of its market cap.

    Total Valuation

    Market Cap$7.67M
    Latest price (Nov 17, 2026)$3.18

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 16.80% in the quarter ended Sep 30, 2026 and grew 350.49% a year over 2 years.

    Shares Outstanding1.81M
    Shares Change (YoY)+28666.26%
    Shares Change (QoQ)+16.80%
    Share Count Growth (2Y CAGR)+350.49%

    Price Statistics

    The stock is down 86.18% over 52 weeks and trades 47.87% below its 50-day average.

    Beta (1Y)1.35
    52-Week Change-86.18%
    1-Month Change-52.47%
    3-Month Change-55.66%
    6-Month Change-70.42%
    5-Year Change-99.89%
    Total Return (1Y)-86.18%
    Total Return (3Y CAGR)-73.78%
    Total Return (5Y CAGR)-75.56%
    Return vs SPY (1Y)-92.15%
    Max Drawdown (1Y)-86.18%
    Max Drawdown (3Y)-98.42%
    Sharpe Ratio (1Y)-1.41
    Correlation with SPY (1Y)0.16
    50-Day Average$6.10
    200-Day Average$8.96
    52-Week Range$3.50 to $23.60
    RSI (14 Days)25.9
    Average Volume (20 Days)81.62K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.82x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.82x
    Quick Ratio3.82x
    Debt / Equity0.00x
    Interest Coverage-24.93x

    Returns and Efficiency

    Return on equity is -434.61% and return on assets is -320.90% over the last 12 months.

    Return on Equity (ROE)-434.61%
    Return on Assets (ROA)-320.90%
    Return on Capital Employed (ROCE)-420.08%
    ROIC (5Y Average)-37.33%

    Scores

    GTBP has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$16.46M
    Pretax Income-$33.91M
    Net Income-$33.91M
    EBIT-$32.78M
    Reported EPS (TTM)-$3,051.50

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 73.79% of the $10.57M in total assets.

    Cash and Equivalents$9.92M
    Total Debt$0
    Net Cash$9.92M
    Net Cash Per Share$5.47
    Working Capital$7.80M
    Shareholder Equity$7.80M
    Book Value Per Share$4.30
    Total Assets$10.57M
    Total Liabilities$2.77M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$13.39M
    FCF Per Share-$6.50

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-55.97%
    Tangible Book Per Share Growth (2Y CAGR)-55.97%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-25 reverse split on Sep 8, 2026.

    Last Split DateSep 8, 2026
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About GTBP

    What is GTBP's market cap?

    GT Biopharma has a market cap of $7.67M.

    How many shares of GTBP are outstanding?

    GT Biopharma has 1.81M shares outstanding. The count is up 28666.26% from a year earlier.

    Does GTBP pay a dividend?

    No. GT Biopharma does not pay a dividend.

    How much debt does GTBP have?

    GT Biopharma has $0 of total debt and $9.92M of cash and equivalents, a net cash position of $9.92M.